This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
How many appropriate NovoRapid® patients can switch to Trurapi®?
Number of patients using NovoRapid®
Current annual NovoRapid® spend
Annual spend by switching appropriate patients to Trurapi®
Your annual savings
MAT-GB-2100260 (V1.0) March 2021
What is your current annual
NovoRapid® spend?
Current annual NovoRapid® spend
Annual spend by switching 20% of patients to Trurapi®
Your annual savings
MAT-GB-2100260 (V1.0) March 2021
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com
MAT-XU-2305592 (V1.0) Date of Preparation: October 2023